Extended-Release Buprenorphine Treatments for Opioid Use Disorder

Description

This training provides healthcare teams with information on the available extended-release injectable buprenorphine formulations for the treatment of opioid use disorder and how to implement them into clinical practice.

Topics include the pharmacology and side effects of extended-release injectable buprenorphine formulations; storage, administration, and patient selection processes; dosage, initiation, and maintenance for patients using weekly and monthly injectable doses; and the workflows and administrative tasks involved in implementing extended-release injectable buprenorphine in healthcare settings.

NOTE: This training is 60 minutes long. There will be an optional 30-minute Q&A session following the training, which will not count for credit.

Objectives

Following this training, participants will have the knowledge to:

1. Explain the pharmacology and side effects of injectable buprenorphine formulations.
2. Recall processes of patient selection, storage, and administration of injectable buprenorphine.
3. Develop basic understanding of dosing, initiation and maintenance using weekly and monthly injectable buprenorphine.
4. Identify workflows and administrative requirements for implementing injectable buprenorphine within healthcare settings.

Sponsored by

Boston Medical Center Grayken Center for Addiction TTA, Massachusetts Department of Public Health, Bureau of Substance Addiction Services (DPH/BSAS)

Funding for out of state attendees is provided by the Opioid Response Network (ORN).

Funding for this initiative was made possible (in part) by grant no. 1H79TI085588-02 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

Accreditation information